Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir144
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects61
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas60
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis55
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance54
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update38
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury35
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata35
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?32
Guidance for interactions between antiseizure medications28
Comorbidities and the right dose: antipsychotics27
Hormones, microbes, and PrEP drugs in the female genital tract27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database26
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis24
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals23
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer23
Bioactivity descriptors for in vivo toxicity prediction: now and the future23
A comprehensive review of the efficacy and safety of ertugliflozin22
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury21
0.06030797958374